Eli Lilly reports positive Phase 3 results for retatrutide from TRIUMPH-2 and TRIUMPH-3, plans FDA filing in Q1 2027
Eli Lilly announced topline results from two additional pivotal Phase 3 trials of retatrutide, its investigational triple GIP/GLP-1/glucagon receptor agonist, meeting primary weight-loss and cardiometabolic endpoints in adults with obesity, type 2 diabetes, and established cardiovascular disease. Combined with earlier TRIUMPH-1 data showing 28.3% average weight loss at 80 weeks, the company said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, with a potential approval window in late 2027 to 2028.
This is a summary. The reporting is PR Newswire (Eli Lilly and Company)'s, and the link below goes to the original article.
Read the full article at PR Newswire (Eli Lilly and Company)